Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Pancreatic Neoplasms 2Locally Advanced Rectal Cancer 2Colonic Neoplasms 2Cervical Cancer Metastatic 2Breast Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Salivary Gland Neoplasms 1Recurrence 1Rectal Cancer Patients 1Non-squamous Non-small-cell Lung Cancer 1Mouth Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Gestational Trophoblastic Disease 1Esophageal Squamour Cell Cancer 1Endometrioid Endometrial Cancer 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced Primary Liver Cancer 1

Interventions

Oxaliplatin 66pembrolizumab 47Fluorouracil 44Capecitabine 39Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 20Docetaxel 19Cisplatin 18S 1 (combination) 17Bevacizumab 15Irinotecan 14Drug Therapy 14tislelizumab 12Ramucirumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10sintilimab 9Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8atezolizumab 8Specimen Handling 8Biopsy 8durvalumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Stomach Neoplasms × camrelizumab × 1 year × Clear all
NCT07320586 2026-03-13

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Shandong Tumor Hospital

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
550 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
885 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡